Omega-3 Fish Oil (EPA/DHA).

EPA and DHA carry many double bonds that oxidize easily, and vitamin E is the fat-soluble antioxidant that interrupts that chain reaction both inside the capsule and in the body's membranes. The need for this protection rises with polyunsaturated fat intake, which is why fish oil and a small amount of vitamin E are standard formulation partners.

GLA is an omega-6 that moves through the same desaturase and elongase enzymes and feeds the same eicosanoid signaling pathways as the omega-3s. Taking EPA alongside GLA holds down the rise in arachidonic acid that GLA on its own tends to produce, which is why the two fatty-acid families are often paired to keep eicosanoid output balanced.

Vitamin D3 is fat-soluble and needs dietary lipid to be packaged into the micelles the gut takes up, so the oil in a fish oil capsule can serve as a lipid vehicle for its absorption. The two have been delivered together for generations in cod liver oil, which naturally carries both.

Astaxanthin sits across the lipid bilayer with its polar ends at both surfaces, so it intercepts radicals exactly where EPA and DHA double bonds are vulnerable. It also co-absorbs in the same micelle the oil forms.

CoQ10 uptake depends on a fat vehicle, which the oil supplies, and the quinol form then quenches lipid radicals in the same membranes EPA and DHA populate.

Ascorbate regenerates oxidised vitamin E, and vitamin E is what protects the double bonds in EPA and DHA from peroxidation. The link runs through tocopherol rather than acting on the oil directly.

Glutathione peroxidase is a selenoenzyme that reduces the lipid hydroperoxides forming on polyunsaturated chains, so selenium status sits under the stability of an EPA and DHA load.

DHA circulates and is stored largely as phosphatidylcholine, so choline supply governs how the fatty acid is packaged and moved once absorbed.

Phospholipid emulsifiers reduce droplet size and raise the surface lipase can work on, which lifts uptake of a triglyceride fish oil taken without much dietary fat.

ALA from flax competes for delta-6 desaturase and the elongase chain that produces EPA and DHA. Preformed EPA and DHA skip that bottleneck, so added ALA mostly loads the same slow enzyme.

EPA lowers thromboxane A2 by displacing arachidonic acid while ginkgolides act on platelet activating factor. Both move normal platelet aggregation the same way.

Garlic organosulfur compounds reduce platelet aggregation by their own route, adding to the thromboxane shift EPA produces.

Salicylate from salicin dampens cyclooxygenase-derived thromboxane, the same output EPA reduces through substrate competition, though the salicylate load from bark extract is small.

Carnosic acid and related rosemary diterpenes are the standard natural stabiliser slowing peroxide formation in marine oil during shelf life.

Free iron initiates peroxidation of polyunsaturated chains through Fenton chemistry, and fish oil is the most peroxidation-prone lipid in a formula. The two are usually kept in separate dosage forms.

Triglyceride-form fish oil has to be hydrolysed by pancreatic lipase to free fatty acids and monoglycerides before EPA and DHA can be absorbed. Ethyl esters need the same enzyme and are hydrolysed by it more slowly than triglycerides. Anyone with limited pancreatic enzyme output is limited at that step regardless of the dose on the label.

A mixed enzyme blend supplies the lipase activity that fat absorption depends on. Since EPA and DHA absorption is a fat absorption problem first and a fatty acid question second, enzyme sufficiency sits upstream of everything else on this page. This is textbook physiology rather than a tested supplement combination.

Bile salts emulsify dietary fat into micelles, which is what lets lipase reach the triglyceride surface and what carries the products to the enterocyte. Low bile output limits long-chain fatty acid uptake specifically. Taking fish oil with a fat-containing meal recruits the same mechanism physiologically.

Phosphatidylcholine is both an emulsifier that improves the dispersion of an oil dose and the phospholipid that DHA is most abundantly esterified into in neural and retinal membranes. Choline supply and DHA supply meet at the same molecule. The emulsification part is formulation practice; the membrane part is biochemistry.

Medium-chain triglycerides are a carrier and a co-fat that gives an oil dose something to disperse into, which matters most when fish oil is taken without a meal. They are absorbed by a different route, so they do not compete for the long-chain pathway. This is about the vehicle, not about any additive effect on the fatty acids themselves.

Krill oil delivers EPA and DHA largely as phospholipids rather than triglycerides, along with astaxanthin. Combined with fish oil the EPA and DHA totals add and should be counted together rather than treated as two separate things. The carrier differs, and comparisons of the two carriers are about absorption kinetics, not about different fatty acids.

A concentrated EPA product on top of a mixed fish oil raises the EPA to DHA ratio, and the two fatty acids are not interchangeable: EPA competes more directly with arachidonic acid at the cyclooxygenase and lipoxygenase step while DHA dominates neural and retinal membrane composition. The additive part is the total n-3 intake. The ratio is the part that is actually being manipulated.

Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA and require the carnitine shuttle to enter beta-oxidation. That makes carnitine a structural dependency for oxidising any long-chain fatty acid load, including EPA and DHA. The step is textbook; no combination trial is being invoked.

High-dose EPA and DHA reduce platelet aggregation by shifting thromboxane production, and nattokinase acts on fibrin and clot dynamics. Stacked, the effects on bleeding tendency add rather than cancel. This is the interaction to flag before any procedure and it belongs on the label conversation, not buried.

Gingerols inhibit thromboxane synthesis in laboratory and small human work, the same broad target as high-dose EPA. The two therefore add on platelet function. The size of ginger's contribution at culinary or ordinary supplemental amounts is modest and not well quantified, which is why this sits at promising rather than higher.

Bromelain has described effects on platelet aggregation and fibrinolysis in laboratory work, which overlap with the platelet effect of high-dose marine n-3. Combined, the effect on bleeding tendency is additive. Worth flagging in any joint-comfort stack, where the two often turn up together.

Quercetin inhibits platelet aggregation in laboratory models and is also a lipophilic antioxidant that can slow peroxidation of polyunsaturated fatty acids. Those are two separate interactions with a fish oil, one to note for bleeding tendency and one potentially useful in the container and the membrane. Both come from preclinical work rather than human combination trials.

Free fatty acids form insoluble calcium soaps in the gut lumen, which is why large calcium doses and free fatty acid preparations taken together reduce the absorption of both. Triglyceride and ethyl ester fish oils are less exposed to this because the fatty acids are esterified until lipase acts. Separating a large calcium dose from a fish oil dose sidesteps the question.

Activated charcoal adsorbs non-specifically in the gut and reduces the absorption of lipophilic compounds taken at the same time. That includes an oil dose. Charcoal is a dose-separation problem for essentially everything, and fish oil is no exception.

Clay binders adsorb and sequester material in the gut lumen, which reduces the amount of a co-administered lipophilic dose that reaches the enterocyte. The interaction is generic to binders rather than specific to marine oils. Take them at separate times.

Viscous soluble fibre slows gastric emptying and micelle formation and binds bile acids, all of which can reduce fat absorption from a dose taken alongside it. The fatty acids are not destroyed, their uptake is slowed and partly reduced. In practice a couple of hours between doses removes the concern.

B12 supports remethylation of homocysteine to methionine, and DHA has to be esterified into phosphatidylcholine by a pathway that draws on methyl donors. Trial work in older adults has reported that B vitamin status and n-3 status interact on cognitive endpoints, which is an interaction observed on markers and test scores rather than a settled mechanism. Listed as a modifier, not a multiplier.

Folate feeds the same remethylation cycle as B12 and therefore the same methyl donor pool that phosphatidylcholine synthesis draws on. The overlap with DHA handling is real biochemistry with an interaction signal in trials of B vitamins and n-3 together. What is measured is homocysteine and test performance, both markers of process rather than structural outcomes.

Curcumin and EPA both act on inflammatory mediator production, curcumin largely through transcriptional signalling and EPA by changing the fatty acid substrate available to cyclooxygenase and lipoxygenase. Different doors to an overlapping output, which is why they appear in the same formulas. Curcumin also has a mild platelet effect, so the bleeding-tendency note applies here too.

Boswellic acids inhibit 5-lipoxygenase, the enzyme that converts arachidonic acid to leukotrienes, while EPA reduces the arachidonic acid available to that enzyme and yields less potent products from it. The two hit the same branch from opposite sides. Human work is on joint comfort and mobility measures and is modest in size.

MSM and marine n-3 are both used for joint comfort and mobility during activity and are routinely combined. There is no shared biochemical step to point to, only overlapping use and separate small trials for each. Listed as an additive-use pairing at promising confidence rather than as a mechanistic synergy.

Glucosamine supplies a substrate for glycosaminoglycan synthesis in cartilage matrix while n-3 fatty acids act on eicosanoid signalling in the same tissue environment. The pairing is one of the most common in joint formulas. Endpoints in the human work are comfort and mobility scores, not imaging of structure.

Arginine is the substrate for nitric oxide synthase, and marine n-3 improves endothelial nitric oxide availability by a different route. Combined they push on vascular tone from two directions, so the blood pressure effects add. That is worth knowing for anyone already managing blood pressure with a clinician.

Dietary nitrate is reduced to nitrite and then to nitric oxide independently of nitric oxide synthase, and fish oil acts on endothelial function separately. Stacked, their effects on blood pressure are additive rather than redundant. Both are measured as blood pressure, a marker followed over weeks.

Taurine is abundant in the same marine tissues as EPA and DHA and acts as a membrane stabiliser and osmolyte, including in retina and myocardium where DHA is also concentrated. The co-location is real and the functional interaction is inferred rather than demonstrated. Promising, on mechanism and shared tissue distribution.

Six double bonds make DHA one of the most peroxidation-prone fatty acids in the body, so any n-3 load raises the demand on the antioxidant network that protects membrane lipids. Lipoic acid moves between the water and lipid phases and helps regenerate both ascorbate and tocopherol. This is a protection argument, not a claim that lipoic acid increases n-3 activity.

Purified fish body oil carries little iodine, but marine sources generally and fish liver oils in particular sit alongside iodine in the diet, and cod liver oil also carries vitamins A and D. Reading a marine oil's whole nutrient contribution matters more than reading its EPA and DHA line alone. This is a composition point about the source material, not a biochemical interaction.